- FTC Expands Patent Listing Challenges, Targeting More Than 300 Junk Listings for Diabetes, Weight Loss, Asthma and COPD Drugs ( )
- Federal Agencies Launch Portal for Public Reporting of Anticompetitive Practices in the Health Care Sector ( )
- Alcohol Addiction Treatment Firm will be Banned from Disclosing Health Data for Advertising to Settle FTC Charges that It Shared Data Without Consent ( )
- FTC, HHS Extend Public Comment Period on Generic Drug Shortages and Competition Request for Information ( )
- Federal Trade Commission, the Department of Justice and the Department of Health and Human Services Launch Cross-Government Inquiry on Impact of Corporate Greed in Health Care ( )
- FTC Hosts March 5 Virtual Workshop on Private Equity in Health Care ( )
- FTC Releases Agenda for Virtual Workshop on Private Equity in Health Care ( )
- FTC Action Leads to Ban for Company and Its Owner Who Failed to Ship PPE ‘Next Day’ at Height of Pandemic ( )
- FTC Sends Almost 160,000 Claim Forms to Consumers Who Could Receive Money Under a Settlement with LasikPlus Providers Over Deceptive Price Advertising ( )
- FTC to Host Virtual Workshop on Private Equity in Health Care ( )
- FTC, HHS Seek Public Comment on Generic Drug Shortages and Competition Amongst Powerful Middlemen ( )
- FTC Obtains $195 Million Judgment, Permanent Ban on Telemarketing and Selling Healthcare Products Against Simple Health Over Charges It Sold Sham Health Insurance ( )
- FTC Submits Comment on March-In Rights to Promote Efforts to Lower Drug Prices ( )
- FTC Sues to Block Novant Health’s Acquisition of Two Hospitals from Community Health Systems ( )
- Statement on Second Circuit Order Upholding “Pharma Bro” Martin Shkreli’s Lifetime Ban ( )
- Statement Regarding the Termination of John Muir’s Takeover of San Ramon Regional Medical Center from Tenet Healthcare ( )
- Statement Regarding Illumina’s Decision to Divest Grail ( )
- FTC Approves Final Order Settling Horizon Therapeutics Acquisition Challenge ( )
- Statement Regarding the Termination of Sanofi’s Proposed Acquisition of Maze Therapeutics’ Pompe Disease Drug ( )
- FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that Threatens Sanofi’s Monopoly ( )
- FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings ( )
- FTC Sues to Block John Muir Health’s Takeover of San Ramon Regional Medical Center ( )
- FTC Challenges More Than 100 Patents as Improperly Listed in the FDA’s Orange Book ( )
- FTC Sends Nearly $7 Million in Refunds to Consumers Harmed by Medical Discount Plans Sold as Health Insurance ( )
- FTC Issues Policy Statement on Brand Pharmaceutical Manufacturers’ Improper Listing of Patents in the Food and Drug Administration’s ‘Orange Book’ ( )
- Statement Regarding Termination of CooperCompanies’ Attempted Acquisition of Cook Medical’s Reproductive Health Business ( )
- FTC Reaches Proposed Settlement with Surescripts in Illegal Monopolization Case ( )
- FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy ( )
- FTC Sues to Block IQVIA’s Acquisition of Propel Media to Prevent Increased Concentration in Health Care Programmatic Advertising ( )
- Federal Trade Commission Withdraws Health Care Enforcement Policy Statements ( )
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.